SCHEMBL720768

SCHEMBL720768

c1ccc(COC2CCC3(CC2)OCCO3)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.56
OPRL1 P41146 2/20 0.56
DPP4 P27487 1/20 0.56
SIGMAR1 Q99720 2/20 0.50
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
CARM1 Q86X55 2/20 0.43
PRMT6 Q96LA8 2/20 0.43
TMEM97 Q5BJF2 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
CTSK P43235 2/20 0.43
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
C5AR1 P21730 2/20 0.41
EPHX2 P34913 1/20 0.40
CTSV O60911 1/20 0.39
CTSS P25774 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10686275 0.94 OPRM1 (0.54) OPRM1OPRL1DPP4SIGMAR1CYP2C9
SCHEMBL5514770 0.84 CARM1 (0.46) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL16985344 0.83 CTSL (0.45) OPRM1OPRL1DPP4SIGMAR1CYP2C9
SCHEMBL16969171 0.83 OPRM1 (0.43) OPRM1OPRL1DPP4SIGMAR1CYP2C9
SCHEMBL5524763 0.83 CARM1 (0.50) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL20859043 0.82 CYP2C9 (0.44) OPRM1OPRL1DPP4SIGMAR1CYP2C9
SCHEMBL8990348 0.80 CARM1 (0.53) SIGMAR1CARM1PRMT6TMEM97
SCHEMBL5521291 0.79 CARM1 (0.48) OPRM1OPRL1DPP4CARM1PRMT6
SCHEMBL6469380 0.78 OPRM1 (0.59) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL1809933 0.78 CTSL (0.45) CYP2C9CYP2C19CTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3782994-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2025-07-16 EP disclosed
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 US disclosed
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 CN disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 US disclosed
CN-114591242-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-01-07 CN disclosed
CN-114634447-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-11-15 CN disclosed
CN-113636978-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
CN-113603645-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 CN disclosed
US-7211694-B2 Substituted 4-aminocyclohexanols GRUENENTHAL GMBH (DE) 2007-05-01 US disclosed
WO-2007001958-A2 STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING EMORY UNIVERSITY (US) 2007-01-04 WO disclosed
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors INCYTE HOLDINGS CORPORATION 2006-11-09 US disclosed
US-20050187220-A1 Substituted 4-aminocyclohexanols GRUENENTHAL GMBH (DE) 2005-08-25 US disclosed
EP-1565436-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2005-08-24 EP disclosed
EP-1487778-A1 SUBSTITUTED 4-AMINOCYCLOHEXANOLS Grünenthal GmbH (DE) 2004-12-22 EP disclosed
WO-2004050024-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2004-06-17 WO disclosed
WO-2003080557-A1 SUBSTITUTED 4-AMINOCYCLOHEXANOLS Grünenthal GmbH (DE) 2003-10-02 WO disclosed
US-6211219-B1 DRUGS, ANALGESICS AND AGONISTS MERCK SHARP & DOHME LTD. (GB) 2001-04-03 US disclosed
US-5536725-A Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines FMC CORPORATION (US) 1996-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK OPRM1 4852/4885OPRL1 3242/4885DPP4 3328/4885
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors CCR2, CXCR3, CCR5 OPRM1 277/4885OPRL1 158/4885DPP4 2633/4885
US-20050187220-A1 Substituted 4-aminocyclohexanols ADRA2C, OPRK1, OPRD1 OPRM1 6/4885OPRL1 4/4885DPP4 847/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK OPRM1 4852/4885OPRL1 3242/4885DPP4 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.